CRISPR Therapeutics
CRSP
182 hedge funds and large institutions have $1.13B invested in CRISPR Therapeutics in 2019 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 51 reducing their positions, and 29 closing their positions.
7% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 29
4% more call options, than puts
Call options by funds: $23.9M | Put options by funds: $22.9M
1% more funds holding
Funds holding: 181 → 182 (+1)
0% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 51
1.43% less ownership
Funds ownership: 51.82% → 50.39% (-1.4%)
12% less capital invested
Capital invested by funds: $1.29B → $1.13B (-$158M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$43.3M |
| 2 |
O
OrbiMed
New York
|
+$24.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$18.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$17.1M |
| 5 |
AC
Armistice Capital
New York
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$75.8M |
| 2 |
A
Abingworth
London,
United Kingdom
|
-$25.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$14.2M |
| 4 |
JP Morgan Chase
New York
|
-$6.07M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.17M |
CRSP Hedge Fund Activity: Q3 2019 in Review
182 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2019, worth a combined $1.13B — down 12% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CRSP positions and 29 closed out — a net gain of 2 holders — while 51 added to existing stakes and 51 trimmed.
The largest buyer was Nikko Asset Management Americas, adding an estimated $43.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $75.8M sold.
- 182 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2019, up from 181 in Q2 2019.
- Funds reported $1.13B of CRISPR Therapeutics stock for Q3 2019, down 12% quarter-over-quarter.
- 31 funds opened new CRISPR Therapeutics positions in Q3 2019 and 29 closed out, a net change of +2 holders.
- The largest CRISPR Therapeutics buyer in Q3 2019 was Nikko Asset Management Americas, an estimated $43.3M added.
- The largest CRISPR Therapeutics seller in Q3 2019 was EcoR1 Capital, an estimated $75.8M sold.
Based on aggregated 13F filings for Q3 2019.